AI Stock Monitor
AMGN - Amgen
Amgen is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Biotechnology · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NASDAQ · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.Price History
AMGN chart
AI-Assisted Chart Analysis
Amgen technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Mixed trend: the latest level is below its 20-period average, without full long-term confirmation.
RSI is 31, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 435.64. A break below 375.65 invalidates the near-term support setup.
The first resistance/watch zone is 478.48. A confirmed break above 478.48 supports continuation.
Annualized realized volatility is +32.9%. Maximum lookback drawdown is -15.4%, from a high-water mark of 444.12 to 375.65.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported AMGN at 435.64 USD; the latest daily move fell -0.72%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified -0.72% daily move is current market context for Amgen.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The current evidence-grounded AI read is bearish.
- Evidence: The MariTide trial progression is a significant fundamental development that could drive future revenue growth, but it is still in the clinical phase, meaning commercial success is not guaranteed.
- Uncertainty: The competitive threat to Tepezza from Viridian Therapeutics is a notable risk that warrants close monitoring, as it could impact the company's ability to sustain margins in its bone and inflammation health segments.
- Watch: Investors should look for further updates on the MariTide trial data and any potential impact from the securities litigation settlement on the balance sheet.
Key Risks
- Competitive erosion of the Tepezza franchise by new entrants like Viridian Therapeutics could lead to market share loss and margin pressure.
- Clinical trial failure or delays for the MariTide program would significantly impair the company's growth prospects in the lucrative obesity market.
- Ongoing legal and regulatory scrutiny, including the current securities litigation, poses a risk of financial penalties and potential reputational damage.
- Broader market volatility and sector-specific rotation could impact Amgen's stock price, independent of its fundamental performance.
Upcoming Catalysts
- Top-line results from the Phase 3 MariTide trials will be the primary catalyst for re-rating the company's growth potential in the obesity market.
- Future earnings reports will be critical to assess the impact of competition on Tepezza and other key revenue drivers.
- Any further developments or finalization of the securities litigation settlement will provide clarity on potential financial liabilities.
- Strategic capital allocation decisions, such as M&A activity or changes to the dividend policy, could influence investor sentiment and valuation.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceAnalyst OpinionInvestors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Zacks Investment Research · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceSocial Signal@Amgen - X · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceSocial SignalđżđŚ Jayden Schaper (Alfred Dunhill Championship) đżđŚ Casey Jarvis (Investec South African Open Championship) đŠđ° Jeff Winther (Danish Golf Championship) đ´ó §ó ˘ó łó Łó ´ó ż Scott Jamieson (Nexo Golf Championship) đŽđŞ Shane Lowry (Amgen Irish Open) đ´ó §ó ˘ó Ľó Žó §ó ż Joe Dean ( - X · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceAnalyst OpinionInvestors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Zacks Investment Research · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceSocial SignalEvery shot of Shane Lowry's final three holes as he went on to win the 2026 Amgen Irish Open by 11 shots đ - X · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.
